Valuation: Talphera, Inc.

Market Cap 61.77M 53.53M 50.59M 45.93M 86.08M 5.93B 86.6M 604M 233M 3.01B 232M 227M 9.58B P/E 2026 *
-5.49x
P/E 2027 * -5.47x
Enterprise Value 61.77M 53.53M 50.59M 45.93M 86.08M 5.93B 86.6M 604M 233M 3.01B 232M 227M 9.58B EV / Sales 2026 *
-
EV / Sales 2027 * 138x
Free-Float
78.59%
Yield 2026 *
-
Yield 2027 * -
1 week-2.46%
1 month-3.25%
3 months+29.18%
6 months+50.16%
Current year+4.39%
1 week 1.16
Extreme 1.16
1.26
1 month 1.16
Extreme 1.16
1.28
Current year 0.69
Extreme 0.6866
1.5
1 year 0.69
Extreme 0.6866
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
21.6
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 2017-03-05
Director of Finance/CFO 56 2017-07-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 60 2006-07-31
Director/Board Member 72 2010-01-31
Chairman 75 2013-02-10
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/26 Tax

Chief Technology Officer

-4,518 0.0090%
4/2/26 Tax

Chief Executive Officer

9,938 0.0199%
4/2/26 Tax

Chief Technology Officer

2,444 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.46%+21.43%+29.35% 61.77M
+0.78%-1.78%+78.70%+34.77% 355B
+0.61%-0.75%+23.72%-20.42% 65.7B
+2.06%+0.98%+42.97%+176.49% 12.06B
+1.17%+1.65%-5.94%-17.01% 7.56B
+0.13%-6.68%-29.36%-14.35% 4.49B
-2.52%-3.38%-35.21%+7.50% 4.34B
+2.21%+0.06%-32.05%-13.89% 2.9B
+0.24%-1.64%-5.93%+41.57% 2.4B
+1.25%-0.71%-26.04%-32.99% 1.92B
Average +0.58%-1.80%+3.23%+19.10% 45.62B
Weighted average by Cap. +0.76%-1.65%+64.69%+28.41%

Financials

2026 *2027 *
Net sales - 447K 387K 366K 332K 623K 42.88M 627K 4.37M 1.69M 21.75M 1.68M 1.64M 69.33M
Net income -15.61M -13.53M -12.78M -11.61M -21.75M -1.5B -21.88M -153M -58.98M -759M -58.63M -57.33M -2.42B -18.63M -16.15M -15.26M -13.86M -25.97M -1.79B -26.12M -182M -70.41M -907M -70M -68.44M -2.89B
Net Debt - -
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
26-09-16 US$1.190 0.00% 228,058
26-09-15 US$1.190 -4.03% 164,590
26-09-14 US$1.240 0.00% 25,671
26-09-11 US$1.240 0.00% 151,336
26-09-10 US$1.240 +1.64% 217,152
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.190USD
Average target price
3.125USD
Spread / Average Target
+162.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TLPH Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!